354 related articles for article (PubMed ID: 19027219)
1. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
[TBL] [Abstract][Full Text] [Related]
2. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and chronic prostatic diseases: evidence for a link?
Sciarra A; Di Silverio F; Salciccia S; Autran Gomez AM; Gentilucci A; Gentile V
Eur Urol; 2007 Oct; 52(4):964-72. PubMed ID: 17618043
[TBL] [Abstract][Full Text] [Related]
4. The correlation between metabolic syndrome and prostatic diseases.
De Nunzio C; Aronson W; Freedland SJ; Giovannucci E; Parsons JK
Eur Urol; 2012 Mar; 61(3):560-70. PubMed ID: 22119157
[TBL] [Abstract][Full Text] [Related]
5. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
7. Obesity and prostate cancer: epidemiology and clinical implications.
Buschemeyer WC; Freedland SJ
Eur Urol; 2007 Aug; 52(2):331-43. PubMed ID: 17507151
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL
Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871
[TBL] [Abstract][Full Text] [Related]
9. [Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].
Yang L; Zhao K; Zhang A; Liu LR; Liu ZH; Han P; Wei Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):760-3, 768. PubMed ID: 24325107
[TBL] [Abstract][Full Text] [Related]
10. Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia.
Lagiou A; Samoli E; Georgila C; Minaki P; Barbouni A; Tzonou A; Trichopoulos D; Lagiou P
Eur J Cancer Prev; 2008 Aug; 17(4):336-9. PubMed ID: 18562958
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
12. Review of exercise and the risk of benign prostatic hyperplasia.
Sea J; Poon KS; McVary KT
Phys Sportsmed; 2009 Dec; 37(4):75-83. PubMed ID: 20048544
[TBL] [Abstract][Full Text] [Related]
13. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammation in benign prostatic hyperplasia: implications for therapy.
Wang L; Yang JR; Yang LY; Liu ZT
Med Hypotheses; 2008; 70(5):1021-3. PubMed ID: 17935901
[TBL] [Abstract][Full Text] [Related]
15. [Expression of VEGF in prostate cancer and its correlation with ET-1].
Zhou WQ; Yin HL; Zhang ZY; Yi XM; Ge JP; Zhou SG; Cheng W; Wei W; Ma HQ; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):987-92. PubMed ID: 19102498
[TBL] [Abstract][Full Text] [Related]
16. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension.
Boyle P; Napalkov P
Scand J Urol Nephrol Suppl; 1995; 168():7-12. PubMed ID: 7541551
[TBL] [Abstract][Full Text] [Related]
17. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen.
Minnery CH; Getzenberg RH
J Urol; 2005 Jul; 174(1):375-9. PubMed ID: 15947693
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
19. Lower urinary tract symptoms, obesity and the metabolic syndrome.
Moul S; McVary KT
Curr Opin Urol; 2010 Jan; 20(1):7-12. PubMed ID: 19904208
[TBL] [Abstract][Full Text] [Related]
20. [Benign hypertrophy of the prostate: pathogenic aspects].
Páez Borda A; Fernández Lucas C; Diego García A; Prieto Chaparro L; Gómez Ruiz JJ; Rapariz González M; Silmi Moyano A; Salinas Casado J; Blázquez Izquierdo J; Usón Calvo A
Arch Esp Urol; 1991 Apr; 44(3):229-36. PubMed ID: 1714264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
